http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2360818-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-76 |
| filingDate | 2006-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f3e6abc5705ae9aed77346dc6c7f508 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32fcd428641a653b7df4163e57dc565d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6b781b0524771b53695f7fca21d82bf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5752d023961cb420d32c7bdc816c2cde |
| publicationDate | 2011-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2360818-T3 |
| titleOfInvention | MIMETICS OF LINEAR UREA ANTAGONISTS OF THE P2Y RECEIVER, USEFUL IN THE TREATMENT OF THROMBOTHIC AFFECTIONS. |
| abstract | A compound of Formula (I): ** Formula ** or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate thereof, wherein: ring A is substituted with 0-4 R1 and is selected from: substituted with 0 -3 R7; 10 W is -NHCOCH = CH-, -NHCO-, -NHCO2-, -NHCO2CH2-, -NHCON (Me) -, -NHCOCH2NH-, -NHCOCH (Me) -, NHCOCH2CH2-, -NHCOCH2CONH-, -NHCH2-, -NHCH2CH2CH2-, -NHSO2-, -NHSO2NH-, -NHSO2CH2-, and ring B is NHSO2CH = CH-, -NHCONHNHCO-, -CH2CONH-, R1 is, independently whenever it is present, F, Cl, Br, I, CF3, -CF2CF3, OCF3, -OCF2CF2H, OCF2CF3, SiMe3, (CRfRf) r-ORc, SRc, CN, NO2, - (CRfRf) r-NR12R13, - (CRfRf) rC (O) Rc, - (CRfRf ) r-CO2Rc, - (CRfRf) rC (O) NR12R13, -OP (O) (OEt) 2, 4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl, C1-8 alkyl substituted with 0 -2 Ra, C2-8 alkenyl substituted with 0-2 Ra, C2-8 alkynyl substituted with 0-2 Ra, - (CRfRf) r-carbocycle C3-13 substituted with 0-5 Rb or (CRfRf) r-heterocycle 5 to 10 members comprising: carbon atoms and 1-4 heteroatoms selected from N, NR11, O and S (O) p, said heterocycle being substituted with 0-5 Rb; alternatively, two R1s are two adjacent carbon atoms combined with the carbon atoms to which they are attached, they form a 5- or 7-membered carbocycle or heterocycle comprising: additional carbon atoms and 0-3 heteroatoms selected from N, NR11 , O and S (O) p and 0-2 carbonyl groups, said carbocycle or heterocycle being substituted with 0-4 Rb; R6 is 2-f-Bu-Ph; R7 is, independently each time it is present, F, Cl, Br, I, OCF3, CF3, ORc, SRc, CN, NO2, -NR12R13, C (O) Rc, -C (O) ORc, -C (O ) NR12R13, -NR14C (O) Rd, -S (O) pNR12R13, -S (O) Rd, -S (O) 2Rd, C1-8 alkyl substituted with 02 Ra, C2-8 alkenyl substituted with 0-2 Ra , C2-8 alkynyl substituted with 0-2 Ra, - (CH2) r-C3-7 cycloalkyl substituted with 0-3 Rb, - (CH2) C3-7 rhenyl substituted with 0-3 Rb or - (CH2) r- 5-10 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR7b, O and S (O) p, said heterocycle being substituted with 0-3 Rb; alternatively, two R7s in two adjacent carbon atoms form a 5- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-3 ring heteroatoms selected from O, N, NR7b and S (O) p; R7b is H, C1-4 alkyl, -C (O) (C1-4 alkyl), -C (O) phenyl, -C (O) benzyl or benzyl; R11 is, independently each time it is present, H, C1-6 alkyl substituted with 1-5 fluorine, (CRfRf) rC (O) NR12R13, C1-8 alkyl substituted with 0-2 Ra, -C (O) (CH2 ) n (C3-6 cycloalkyl), -C (O) (CH2) nphenyl, C (O) O (C1-8 alkyl), -C (O) O (CH2) n (C3-6 cycloalkyl), -C (O) O (CH2) nphenyl, -C (O) O (CH2) 2-4 (C1-4 alkyl), C (O) NH (C1-6 alkyl), -S (O) 2 (C1- alkyl 6), -S (O) 2 (CH2) nphenyl, - (CRfRf) C3-7 cycloalkyl, - (CRfRf) rphenyl or (CRfRf) 5 or 6 membered heterocycle; said alkyl, cycloalkyl, phenyl and aryl substituted with 0-2 Rb and said heteroaryl and heterocycle substituted with 0-2 Rb and comprising: carbon atoms and 1-4, heteroatoms selected from N, NRfO and S (O) p ; R12 is, independently each time it is present, H, C1-6 alkyl substituted with 1-5 fluorine, (CRfRf) rC (O) NR12R13, C1-6 alkyl, -C (O) (C1-6 alkyl), - C (O) (CH2) n (C6-10 aryl), -C (O) (CH2) n (5-10 membered heteroaryl), -C (O) O (C1-4 alkyl), - (CH2) nC (O) NH (C1-6 alkyl), - (CH2) nC (O) NH (C6-10 aryl), (CH2) nC (O) NH (5-10 membered heteroaryl), -S (O) 2 (C1-6 alkyl), -S (O) 2 (CH2) n (C6-10 aryl), S (O) 2 (CH2) n (5-10 membered heteroaryl), - (CH2) n- ( C6-10 aryl) or - (CH2) 5 to 10 membered n-heteroaryl; said alkyl and aryl being substituted with 0-2 Rg; and said heteroaryl being substituted with 0-2 Rg and comprises: carbon atoms and 1-4 heteroatoms selected from N, NR11, O and S (O) p; R13 is, independently each time it is present, H, C1-6 alkyl or - (CH2) n-phenyl; alternatively, R12 and R13, when bound to the same nitrogen, combine to form a 5-10 membered heterocyclic ring comprising: carbon atoms and 1-2 additional heteroatoms selected from N, NR11, O and S (O) p; R14 is, independently each time it is present, H, C1-6 alkyl or - (CH2) r-phenyl; Ra is, independently each time it is present, F, OCF3, CF3, ORc, SRc, CN, -NR12R13, -C (O) Rc, C (O) ORc, -C (O) NR12R13, -NR14C (O) Rd, -S (O) pNR12R13, -S (O) Rd, -S (O) 2Rd, - (CH2) r-carbocycle C3-10 substituted with 0-3 Re or - (CH2) r-heterocycle from 5 to 10 members comprising: carbon atoms and 1-4 heteroatoms selected from N, NRf, O and S (O) p, said heterocycle being substituted with 0-3 Re; Rb is, independently each time it is present, H, = O, F, Cl, Br, I, - (CH2) r-ORc, SRc, CN, NO2, CF3, OCF3, - (CH2) r-NR12R13, - C (O) Rc, - (CH2) rC (O) ORc, - (CH2) rC (O) NR12R13, -NR14C (O) Rd, -S (O) pNR12R13, -S (O) Rd, S (O ) 2Rd, C1-4 haloalkyl, C1-4 haloalkyloxy, C1-4 alkyloxy, C1-4 alkylthio, C1-4-C alkyl (O) -, C1-4-OC alkyl (O) -, C1 alkyl -4-C (O) NH-, C1-8 alkyl substituted with 0-2 Ra, C2-8 alkenyl substituted with 0-2 Ra, C2-8 alkynyl substituted with 0-2 Ra, - (CH2) C3- carboxy 10 substituted with 0-3 Re, or - (CH2) 5 to 10 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NRf, O and S (O) p, said heterocycle being substituted with 0 -3 Re; Rc is, independently each time it is present, H, -OP (O) (OEt) 2, C1-8 alkyl substituted with 0-3 Re, C2-8 alkenyl substituted with 0-3 Re, C2-8 alkynyl substituted with 0-3 Re, - (CRfRf) r-C3-8 cycloalkyl substituted with 0-3 Re, - (CRfRf) r-C6-10 aryl substituted with 0-3 Re or - (CRfRf) r-heterocycle from 5 to 10 members comprising: carbon atoms and 1-4 heteroatoms selected from N, NRf, O and S (O) p, said heterocycle being substituted with 0-3 Re; Rd is, independently each time present, CF3, OH, C1-4 alkoxy, C1-6 alkyl, - (CH2) C3-10 carboxy substituted with 0-3 Re or - (CH2) r-heterocycle from 5 to 10 members comprising: carbon atoms and 1-4 heteroatoms selected from N, NRf, O and S (O) p, said heterocycle being substituted with 0-3 Re; Re is, independently each time it is present, H, = O, - (CH2) r-ORf, F, Cl, Br, I, CN, NO2, - (CH2) rNR12R13, -C (O) Rf, - ( CH2) rC (O) ORf-NR14C (O) Rf, - (CH2) rC (O) NR12R13, -SO2NR12R13, -NR14SO2NR12R13, NR14SO2-C1-4 alkyl, -NR14SO2CF3, -NR14SO2-phenyl, -S (O) 2CF3, -S (O) p-C1-4 alkyl, -S (O) p-phenyl, - (CF2) rCF3, C1-8 alkyl substituted with 0-2 Rg, C2-8 alkenyl substituted with 0-2 Rg , C2-8 alkynyl substituted with 0-2 Rg, - (CH2) C3-8 cycloalkyl substituted with 0-2 Rg, - (CH2) r-aryl C6-10 substituted with 0-2 Rg or - (CH2) r- 5-10 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NRf, O and S (O) p, said heterocycle being substituted with 0-2 Rg; alternatively, two Re groups, together with the atoms to which they are attached, form a 5- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-2 heteroatoms selected from N, NRf, O and S (O ) p, 0-1 carbonyl and 0-3 double bonds, said carbocyclic or heterocyclic ring being substituted with 0-3 Rg; Rf is, independently each time it is present, H, F, C1-6 alkyl or - (CH2) n-phenyl; Rg is, independently each time it is present, H, = O, ORf, F, Cl, Br, I, CN, NO2, -NRfRf, -C (O) Rf, C (O) ORf, -NRfC (O) Rf, -C (O) NRfRf, -SO2NRfRf, -NRfSO2NRfRf, -NRfSO2-C1-4alkyl, -NRfSO2CF3, -NRfSO2phenyl, -S (O) 2CF3, -S (O) p-C1-4alkyl, -S (O) p-phenyl, - (CF2) rCF3, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl; n, each time it is present, it is selected from 0, 1, 2, 3 and 4; p, each time it is present, is selected between 0, 1 and 2; and r, each time it is present, is selected from 0, 1, 2, 3 and 4; with the proviso that when W is -NHCOCH2NH-, B is then ring A is distinct from 4-Cl-pyrid-3-yl. |
| priorityDate | 2005-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 909.